Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2016 - 2025)

Fennec Pharmaceuticals filings provide 12 years of Cash from Financing Activities readings, the most recent being $20.8 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 270.35% to $20.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.6 million, a 266.19% increase, with the full-year FY2025 number at $22.6 million, up 266.19% from a year prior.
  • Cash from Financing Activities hit $20.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $1.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $20.8 million in Q4 2025 to a low of -$12.2 million in Q4 2024.
  • Median Cash from Financing Activities over the past 4 years was $229000.0 (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 1186.67% in 2023 and later crashed 686.53% in 2024.
  • Fennec Pharmaceuticals' Cash from Financing Activities stood at $824000.0 in 2022, then soared by 595.39% to $5.7 million in 2023, then plummeted by 313.12% to -$12.2 million in 2024, then surged by 270.35% to $20.8 million in 2025.
  • The last three reported values for Cash from Financing Activities were $20.8 million (Q4 2025), $1.7 million (Q3 2025), and -$284000.0 (Q2 2025) per Business Quant data.